Despite some initial promising early phase results, the development of HDAC inhibitors in lung cancer has been discontinued because of the lack of single‐agent efficacy and the lack of a biomarker that would facilitate patient selection.7, 8. This evidence concerns the gene HDAC9 and lung cancer.